A new vision of drug discovery and development

European Pharmaceutical Review

Volumn 17, Issue 6, 2012, Pages

  Lansing Taylor, D ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL PRODUCT;

ARTICLE; BIOLOGY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; EXPERIMENTAL THERAPY; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL TECHNOLOGY; NONHUMAN; PUBLIC-PRIVATE PARTNERSHIP; QUANTITATIVE ANALYSIS; QUANTITATIVE SYSTEMS PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY; UNIVERSITY HOSPITAL;

EID: 84876233153     PISSN: 13608606     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (40)

1. Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S, Schacht A. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 2010;9:203-14.
2. Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug discovery. 2009;8(12):959-68.
3. Butcher E. Can cell systems biology rescue drug discovery? Nature Reviews Drug Discovery 2005;4:461-7.
4. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacyeffectiveness gap: a regulator's perspective on addressing variability of drug response. Nature Reviews Drug Discovery. 2011;10(7):495-506.
5. Vallance P, Williams P, Dollery C. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin Pharmacol Ther. 2010;87(5):525-7.
6. Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. Nature Reviews Drug Discovery. 2011;10(6):409-10.
7. Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87(3):356-61. PMCID: 2953249.
8. Edmondson G, Valigra L, Kenward M, Hudson R, Belfield H. Making industry-university partnerships work: Science/Business Innovation Board, AISBL; 2012 Contract No.: Document Number.
9. Taylor DL. A personal perspective on high-content screening (HCS): from the beginning. J Biomol Screen. 2010;15(7):720-5.
10. Taylor D. Past, Present, and Future of High Content Screening and the Field of Cellomics. In: Taylor D, Haskins J, Giuliano K, editor. Methods in Molecular Biology, 2007; 356: 3-18. High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery. Totowa, NJ: Humana Press.
11. Alcock P, Bath C, Blackett C, Simpson P. High content cell based primary screening for oncology targets-a perspective. European Pharmaceutical Review. 2010;3.
12. Swinney D, Anthony J. How were new medicines discovered? Nature Reviews Drug Discovery. 2011;10.
13. Lee J, Uhlik M, Moxham C, Tomandl D, Sall D. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. Journal of Medicinal Chemistry. 2012;55:4527-38.
14. Gough A, Taylor D, et al. High Content Screening. The Molecular Basis of Cancer: Elsevier; In Press.
15. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol. 2010;28(5): 237-45.
16. Grskovic M, Javaherian A, Strulovici B, Daley GQ. Induced pluripotent stem cells-opportunities for disease modelling and drug discovery. Nature Reviews Drug Discovery. 2011;10(12):915-29.
17. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ. Multidimensional drug profiling by automated microscopy. Science. 2004;306(5699):1194-8.
18. Giuliano KA, Chen YT, Taylor DL. High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of P53 activation in the cellular response to anticancer drugs. J Biomol Screen. 2004;9(7):557-68.
19. Loo LH, Lin HJ, Steininger RJ 3rd, Wang Y, Wu LF, Altschuler SJ. An approach for extensibly profiling the molecular states of cellular subpopulations. Nat Methods. 2009;6(10):759-65. PMCID: 2818727.
20. Yang R, Niepel M, Mitchison TK, Sorger PK. Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin Pharmacol Ther. 2010;88(1):34-8. PMCID: 2941986.
21. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505-21.
22. Sorger P, Allerheiligen S. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. National Institutes of Health White Paper. 2011.
23. van der Graaf PH, Benson N. Systems pharmacology: bridging systems biology and pharmacokineticspharmacodynamics (PKPD) in drug discovery and development. Pharm Res. 2011;28(7):1460-4.
24. Pujol A, Mosca R, Farres J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci. 2010;31(3):115-23.
25. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90.
26. Murphy RF. An active role for machine learning in drug development. Nat Chem Biol. 2011;7(6):327-30.
27. Faeden J, Blinov M, Hlavacek W. Rule-based modeling of biochemical systems with BioNetGen. In: Maly I, editor. Methods in Molecular Biology: Systems Biology. Totowa, NJ: Humana Press; 2009.
28. Bernards R. A missing link in genotype-directed cancer therapy. Cell. 2012;151(3):465-8.
29. Molina G, Vogt A, Bakan A, Dai W, Queiroz de Oliveira P, Znosko W, et al. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol. 2009;5(9):680-7. PMCID: 2771339.
30. Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W Jr., et al. In silico drug repositioning - what we need to know. Drug Discov Today. 2012;00(00):13-6.
31. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175-81. PMCID: 2784146.
32. Link W, Oyarzabal J, Serelde BG, Albarran MI, Rabal O, Cebria A, et al. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem. 2009;284(41):28392-400. PMCID: 2788888.
33. Zanella F, Rosado A, Garcia B, Carnero A, Link W. Chemical genetic analysis of FOXO nuclearcytoplasmic shuttling by using image-based cell screening. Chembiochem. 2008;9(14):2229-37.
34. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol Biosyst. 2009;5(9):1051-7.
35. Mullard A. Drug repurposing programmes get lift off. Nature Reviews Drug Discovery. 2012;11(7):505-6.
36. Cong F, Cheung AK, Huang SM. Chemical geneticsbased target identification in drug discovery. Annu Rev Pharmacol Toxicol. 2012;52:57-78.
37. Laggner C, Kokel D, Setola V, Tolia A, Lin H, Irwin JJ, et al. Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol. 2012;8(2):144-6. PMCID: 3262069.
38. Vernetti L, Irwin W, Giuliano K, Gough A, Johnston K, Taylor D. Cellular Systems Biology Applied to Pre- Clinical Safety Testing: A Case Study of CellCiphr™ Cytotoxicity Profiling. In: Xu J, Ekins S, editor. Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools. New Jersey: John Wiley and Sons; 2008. p. 53-73.
39. Giuliano K, Gough A, Taylor D, Vernetti L, Johnston K. Early Safety Assessment Using Cellular Systems Biology Yields Insights into Mechanisms of Action. J Biomol Screen. 2010;15:783-97.
40. Prescher JA, Contag CH. Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Curr Opin Chem Biol. 2010;14(1):80-9.